Abstract:Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) pose a severe threat to human health. Our previous research results, as well as those of other research groups, indicated that antibodies (Abs) induced by JEV infection or JEV vaccine vaccination could enhance ZIKV infection in vitro and exacerbate the mortality of ZIKV-infected mice, vice versa, which is known as antibody-dependent enhancement (ADE). Although studies on other flaviviruses revealed that altering the amino acid residues located in the fusion loop (FL) of envelope (E) protein can reduce the level of flavivirus-cross-reactive Abs, thereby abating the ADE of heterologous flavivirus infection, it is unclear whether this strategy is equally applicable to JEV. Methods: In this study, we constructed recombinant adenoviruses and nucleotide-modified mRNA-lipid nanoparticle (LNP) encoding JEV wild-type E protein or E protein mutant (designated as Ad5-JEV-E WT and Ad5-JEV-E mut ; JEV-E WT mRNA-LNP, and JEV-E mut mRNA-LNP). We evaluated the immunogenicity of these vaccine candidates in mice and the capacity of vaccine-immune mouse sera to neutralize JEV infection or mediate ADE of ZIKV infection in vitro and in vivo . Results: Ad5-JEV-E mut or JEV-E mut mRNA-LNP immunization induced ZIKV-cross-reactive Ab response which is dramatically lower than that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The levels of JEV-neutralizing Abs induced by Ad5-JEV-E mut or JEV-E mut mRNA-LNP are comparable to that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The ability of Abs induced by Ad5-JEV-E mut to enhance ZIKV infection in vitro is attenuated as compared with that induced by Ad5-JEV-E WT . Moreover, JEV-E mut mRNA-LNP immunization elicited potent T cell response similar to JEV-E WT mRNA-LNP in mice. Mice immunized with each mRNA-LNP exhibited lower level of serum viral load than the mock-immunized mice post JEV challenge. Mice receiving JEV-E WT mRNA-LNP-immune mouse sera exhibited ADE post ZIKV challenge whereas passively transferred JEV-E mut mRNA-LNP-immune mouse sera did not lead to obvious ADE of ZIKV infection in recipient mice. Most importantly, maternally acquired Abs did not enhance the mortality of 1-day-old neonates born to JEV-E mut mRNA-LNP-immunized mice post ZIKV challenge. Discussion: These results suggest that optimizing the FL sequence of JEV could significantly reduce the level of JEV/ZIKV-cross-reactive Abs and abrogate the ADE of ZIKV infection, providing a promising strategy to develop effective and safety JEV vaccine.

A Novel Recombinant Virus-Like Particles Displaying B and T Cell Epitopes of Japanese Encephalitis Virus Offers Protective Immunity in Mice and Guinea Pigs

Immunization with Pseudotype Baculovirus Expressing Envelope Protein of Japanese Encephalitis Virus Elicits Protective Immunity in Mice

A plasmid encoding Japanese encephalitis virus PrM and E proteins elicits protective immunity in suckling mice.

Protective Immune Responses Induced by an Mrna-Lnp Vaccine Encoding Prm-E Proteins Against Japanese Encephalitis Virus Infection

[Generation of Japanese Encephalitis Virus-like Particle Vaccine and Preliminary Evaluation of Its Protective Efficiency].

Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate

A Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles Elicits Broad Neutralizing Antibody Response in Pigs

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice

Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain

[Secreted Expression of Japanese Encephalitis Virus Prme in Pichia Pastoris and Immunogenicity Evaluation of the Virus-Like Particles in Mice].

Retracted: Immunization With Pseudotype Baculovirus Expressing Envelope Protein Of Japanese Encephalitis Virus Elicits Protective Immunity In Mice (Retracted Article. See Vol 11, Pg 454, 2009)

Baculovirus Surface Display of E Envelope Glycoprotein of Japanese Encephalitis Virus and Its Immunogenicity of the Displayed Proteins in Mouse and Swine Models.

Design And Evaluation Of A Multi-Epitope Peptide Against Japanese Encephalitis Virus Infection In Balb/C Mice

Enhancement of Humoral and Cellular Immunity in Mice Against Japanese Encephalitis Virus Using a DNA Prime–protein Boost Vaccine Strategy

Expression of B cell epitopes of Japanese encephalitis virus and evaluation of its immunogenicity

Enhanced Immune Responses Against Japanese Encephalitis Virus Using Recombinant Adenoviruses Coexpressing Japanese Encephalitis Virus Envelope and Porcine Interleukin-6 Proteins in Mice.

Mutation of Putative N-linked Glycosylation Sites in Japanese Encephalitis Virus Premembrane and Envelope Proteins Enhances Humoral Immunity in BALB/C Mice after DNA Vaccination.

Expression of Porcine parvovirus-like Particles Carrying a CSFV T Cell Epitope and Its Immunization on Mice

Nanoparticle Vaccine Based on the Envelope Protein Domain III of Japanese Encephalitis Virus Elicits Robust Protective Immune Responses in Mice.

Complete protection for mice conferred by a DNA vaccine based on the Japanese encephalitis virus P3 strain used to prepare the inactivated vaccine in China

Porcine Parvovirus Capsid Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles with High Immunogenicity in Mice and Guinea Pigs.